Celcuity Inc. Form 8-K Summary
Business Context and Reporting Period
Date of Report: May 15, 2022
Company: Celcuity Inc. (Nasdaq: CELC)
Event: Entry into a Material Definitive Agreement for a Private Placement of equity securities.
Celcuity Inc., a biopharmaceutical company, entered into a Securities Purchase Agreement to raise capital to advance the clinical development of its lead asset, gedatolisib, specifically for the upcoming Phase 3 VIKTORIA-1 clinical study.
Key Financial Metrics and Transaction Details
Transaction Structure: Private placement of Common Stock, Series A Convertible Preferred Stock, and Warrants.
Gross Proceeds: Approximately $100 million (before fees and expenses).
Securities Issued:
- Common Stock: 6,182,574 shares at $5.75 per share.
- Series A Preferred: 1,120,873 shares at $57.50 per share (convertible at a 10:1 ratio to Common Stock).
- Warrants: Warrants to purchase 695,645 shares of Series A Preferred (equivalent to 6,956,450 Common Shares on an as-converted basis).
Pricing: The purchase price was $5.75 per share on an as-converted basis, representing a premium to the closing price of $5.35 on May 13, 2022.
Warrant Terms: Exercise price set at a 40% premium to the purchase price ($8.05 per Common Share equivalent). Warrants are exercisable immediately and expire 5 years from issuance or 75 days after the announcement of Phase 3 primary endpoint results, whichever is earlier.
Use of Proceeds: Advancing clinical development of gedatolisib (including VIKTORIA-1) and general corporate purposes.
Material Changes and Conditions
Closing Conditions: The closing is expected to occur shortly after the first patient in the VIKTORIA-1 Phase 3 study receives their first dose in the U.S., provided this occurs on or before December 31, 2022. Investors may elect to close prior to the first dose.
Authorized Share Approval: The Company must obtain shareholder approval to increase authorized shares to accommodate conversions and warrant exercises by December 31, 2022. If approved, Warrants may become exercisable for Common Stock directly at an adjusted price of $8.05 per share.
Beneficial Ownership Limitation: Conversion or exercise is restricted if it would cause a holder to beneficially own more than 9.99% of outstanding Common Stock (resettable up to 19.9%).
Guidance, Outlook, and Risks
Clinical Outlook: The Company expects to activate the VIKTORIA-1 study in mid-2022, with the first patient dosed 6 to 10 weeks later. Results for the first primary analysis are expected in the second half of 2024.
Investors: Lead investor is Venrock Healthcare Capital Partners. Other participants include Commodore Capital, NEA, RA Capital Management, Soleus Capital, and CEO Brian Sullivan.
Risks and Contingencies:
- Registration Rights: The Company must file a registration statement for resale of securities within 30 days of closing and authorized share approval. Failure to do so or keep it effective may trigger liquidated damages of 1.0% per 30-day period (capped at 5.0%).
- Dilution: Significant potential dilution exists due to the issuance of Preferred Stock and Warrants, subject to beneficial ownership limits.
- Preferred Stock Rights: Series A Preferred holders have veto rights over certain corporate actions (e.g., amending charter, issuing senior stock) and have priority in liquidation.
Key Facts for Investor Verification
- Verify the exact closing date of the Private Placement and whether the first patient dose in VIKTORIA-1 has occurred.
- Confirm the status of the shareholder vote required to increase authorized shares (deadline: December 31, 2022).
- Monitor the filing and effectiveness of the registration statement for the resale of securities to avoid potential liquidated damages.
- Track the timeline for the VIKTORIA-1 Phase 3 study activation and first patient dosing.
- Review the specific terms of the Series A Preferred regarding liquidation preferences and voting veto rights.